Agios' Rare Anemia Drug Application Under FDA Priority Review

by Vandana Singh, Benzinga Editor

August 18, 2021 7:03 AM | 1 min read |

The FDA has accepted Agios Pharmaceuticals Inc's AGIO marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency.
Under Priority Review designation, the agency's action date is assigned as of February 17, 2022.
Related: Agios Pharma Files US Application For Mitapivat In PK Deficiency.
Mitapivat application is under review with the European Medical Agency for the same indication.
Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents chronic hemolytic anemia, the accelerated destruction of red blood cells.
Related content: Benzinga's Full FDA Calendar.
Price Action: AGIO shares closed 2.38% higher at $44.65 on Tuesday.

Posted In: Biotech News Health Care FDA General Anemia Briefs FDA Priority Review

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.